retatrutide on the market Demand for Unapproved Weight-Loss Drug Surges Social Media Retatrutide Latest Study Released:: People

Summary: Retatrutide's long-term side effects are not yet fully established, but current trial data indicate gastrointestinal effects, increased resting heart rate, and potential risks consistent with the GLP-1 receptor agonist drug class

doi:10.1503/cmaj.080727

However, Epithalon should only be used under medical supervision, as is the case with all peptide therapies

For more information on this subject, please see the full report here if you are a Velocity subscriber Global Consumer - Market Not Yet Losing Appetite for GLP-1 Impacts, Should It

K., Henkel, R., Durairajanayagam, D., Pompeu, C., Madani, S., Belo, A., Singh, N., Covarrubias, S., Darbandi, S., Sadeghi, R., Darbandi, M., Vogiatzi, P., Boitrelle, F., Simopoulou, M., Saleh, R., Shah, R